AnaptysBio

Pioneering the development of therapeutic antibodies generated through natural biology

AnaptysBio is developing novel antibody therapeutics for inflammatory diseases and immuno-oncology indications. The company's products are built on a core in vitro technology that reproduces the body's natural mechanism of antibody generation (somatic hypermutation) to rapidly produce high affinity, high specificity antibodies. AnaptysBio has built a pipeline of proprietary programs against novel targets (including IL-33 and IL-36R) and has also established a collaboration with Tesaro for immuno-oncology targets.

Year of Investment

2007

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

San Diego, California

Website

Social Media